Your browser doesn't support javascript.
loading
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.
Ferreira, João Pedro; Verdonschot, Job; Collier, Timothy; Wang, Ping; Pizard, Anne; Bär, Christian; Björkman, Jens; Boccanelli, Alessandro; Butler, Javed; Clark, Andrew; Cleland, John G; Delles, Christian; Diez, Javier; Girerd, Nicolas; González, Arantxa; Hazebroek, Mark; Huby, Anne-Cécile; Jukema, Wouter; Latini, Roberto; Leenders, Joost; Levy, Daniel; Mebazaa, Alexandre; Mischak, Harald; Pinet, Florence; Rossignol, Patrick; Sattar, Naveed; Sever, Peter; Staessen, Jan A; Thum, Thomas; Vodovar, Nicolas; Zhang, Zhen-Yu; Heymans, Stephane; Zannad, Faiez.
Afiliação
  • Ferreira JP; Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
  • Verdonschot J; Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Portugal (J.P.F.).
  • Collier T; Department of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, the Netherlands (J.V., M.H., S.H.).
  • Wang P; Department of Clinical Genetics, Maastricht University Medical Center, the Netherlands (J.V., P.W.).
  • Pizard A; London School of Hygiene and Tropical Medicine, United Kingdom (T.C.).
  • Bär C; Department of Clinical Genetics, Maastricht University Medical Center, the Netherlands (J.V., P.W.).
  • Björkman J; Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
  • Boccanelli A; Inserm 1024, Institut de Biologie de l'École Normale Supérieure (IBENS), PSL University of Paris, France (A.P.).
  • Butler J; Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Germany (C.B., T.T.).
  • Cleland JG; Casa di Cura Quisisana, Rome, Italy (A.B.).
  • Delles C; TATAA Biocenter AB, Gothenburg, Sweden (J.B.).
  • Diez J; Department of Medicine, University of Mississippi School of Medicine, Jackson (J.B.).
  • Girerd N; Excellence Cluster REBIRTH, Hannover Medical School, Germany (J.B.).
  • González A; Hull York Medical School, Castle Hill Hospital, Cottingham, United Kingdom (A.C.).
  • Hazebroek M; Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, Glasgow, United Kingdom (J.G.C.).
  • Huby AC; National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, University of Glasgow, London, United Kingdom (J.G.C.).
  • Jukema W; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, United Kingdom (C.D.).
  • Latini R; Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain (J.D., A.G.).
  • Leenders J; CIBERCV, Carlos III Institute of Health, Madrid, Spain (J.D., A.G.).
  • Levy D; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain (J.D., A.G.).
  • Mebazaa A; Departments of Nephrology, and Cardiology and Cardiac Surgery, University of Navarra Clinic, Pamplona, Spain (J.D.).
  • Mischak H; Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
  • Pinet F; Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain (J.D., A.G.).
  • Rossignol P; CIBERCV, Carlos III Institute of Health, Madrid, Spain (J.D., A.G.).
  • Sattar N; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain (J.D., A.G.).
  • Sever P; Department of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, the Netherlands (J.V., M.H., S.H.).
  • Staessen JA; Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
  • Thum T; Department of Cardiology, Leiden University Medical Center, the Netherlands (W.J.).
  • Vodovar N; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy (R.L.).
  • Zhang ZY; ACS Biomarker BV, Amsterdam, the Netherlands (J.L.).
  • Heymans S; National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, MA (D.L.).
  • Zannad F; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD (D.L.). UMRS 942, University Paris Diderot.
Circ Heart Fail ; 12(5): e005897, 2019 05.
Article em En | MEDLINE | ID: mdl-31104495
Background Identifying the mechanistic pathways potentially associated with incident heart failure (HF) may provide a basis for novel preventive strategies. Methods and Results To identify proteomic biomarkers and the potential underlying mechanistic pathways that may be associated with incident HF defined as the first hospitalization for HF, a nested-matched case-control design was used with cases (incident HF) and controls (without HF) selected from 3 cohorts (>20 000 individuals). Controls were matched on cohort, follow-up time, age, and sex. Two independent sample sets (a discovery set with 286 cases and 591 controls and a replication set with 276 cases and 280 controls) were used to discover and replicate the findings. Two hundred fifty-two circulating proteins in the plasma were studied. Adjusting for the matching variables age, sex, and follow-up time (and correcting for multiplicity of tests), 89 proteins were found to be associated with incident HF in the discovery phase, of which 38 were also associated with incident HF in the replication phase. These 38 proteins pointed to 4 main network clusters underlying incident HF: (1) inflammation and apoptosis, indicated by the expression of the TNF (tumor necrosis factor)-family members; (2) extracellular matrix remodeling, angiogenesis and growth, indicated by the expression of proteins associated with collagen metabolism, endothelial function, and vascular homeostasis; (3) blood pressure regulation, indicated by the expression of natriuretic peptides and proteins related to the renin-angiotensin-aldosterone system; and (4) metabolism, associated with cholesterol and atherosclerosis. Conclusions Clusters of biomarkers associated with mechanistic pathways leading to HF were identified linking inflammation, apoptosis, vascular function, matrix remodeling, blood pressure control, and metabolism. These findings provide important insight on the pathophysiological mechanisms leading to HF. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02556450.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Proteoma / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Proteoma / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article